IL1B and rheumatoid arthritis: It seems that inhibition of proinflammatory cytokines like IL-1β and intracellular signaling pathways like p38MAPK could be a promising strategy to control inflammatory symptoms in RA (Korb et al., 2006; Moradi et al., 2014).